Skip to main content

AN2 Therapeutics, Inc.

ANTX
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001880438

In the last 90 days, AN2 Therapeutics, Inc. insiders filed 1 open-market purchase and 5 sales; 66 institutions reported holding it in 13F filings for Q2 2026, worth $119.0M in total; no superinvestor holds it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by AN2 Therapeutics, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
1 filing
1 insider, $11.6K in total
Open-market sells
5 filings
3 insiders, $343.0K in total
Insiders trading
4
Net value
−$331.4K
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for AN2 Therapeutics, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for AN2 Therapeutics, Inc.
NameTitleLast reported holdingLast filingFilings, past year
Trenor Cameron C. IIIChief Medical Officer116,667Sep 16, 20261
Readnour Robin ShaneDirector624,765IndirectSep 11, 20265
Williams Sarah JoannePrincipal Accounting Officer66,311Sep 4, 20264
FitzPatrick Margaret MDirector10,708Sep 2, 20263
Zakrzewski Joseph SDirector0IndirectAug 14, 20263
Aziz KabeerDirector59,106Jul 10, 20266
Marks Gilbert LynnDirector81,873Jul 10, 20266
Martin Patricia A.Director18,863Jul 10, 20266
Eizen Joshua MSee Remarks206,554Jul 10, 20265
Spigelman Melvin KDirector–Mar 23, 20262
Wong StephanieDirector–Mar 23, 20262
Chanda SanjayChief Development Officer118,823Mar 23, 20263
Easom EricChief Executive Officer368,630Mar 23, 20262
Day LucyChief Financial Officer118,363Mar 23, 20263
Prior Stephen DavidChief Strategy Officer59,086Jan 7, 20262
Leonard Braden Michael10% Owner3,017,432IndirectJun 16, 20250
RA Capital Healthcare Fund LP10% Owner300,853IndirectAug 13, 20240
Ra Capital Management, L.P.10% Owner300,853IndirectAug 13, 20240
Kolchinsky Peter10% Owner300,853IndirectAug 13, 20240
Shah Rajeev M.10% Owner300,853IndirectAug 13, 20240
RA Capital Nexus Fund II, L.P.10% Owner300,853IndirectAug 13, 20240
Eckburg PaulChief Medical Officer51,416Mar 29, 20240
Krause Kevin MichaelChief Strategy Officer31,914Mar 29, 20240
Adjuvant Global Health Technology Fund, L.P.10% Owner377,542IndirectJan 18, 20240
Adjuvant Global Health Technology Fund DE, L.P.10% Owner377,542IndirectJan 18, 20240
Adjuvant Capital Management, LLC10% Owner377,542IndirectJan 18, 20240
Adjuvant Capital GP, L.P.10% Owner377,542IndirectJan 18, 20240
Nazak Michael AdrianChief Accounting Officer–Feb 17, 20230

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Sep 11, 2026 (view filing)7:45 PM ETSep 92 daysReadnour Robin ShaneDirectorSSale−1.11K$6.02−$6.67K−0.2%624.8K after2 lots10b5-1
Sep 8, 2026 (view filing)7:42 PM ETSep 3-85 daysReadnour Robin ShaneDirectorSSale−16.1K$6.04−$97.3K−2.5%625.4K after4 lots10b5-1
Sep 4, 2026 (view filing)4:25 PM ETSep 13 daysLateWilliams Sarah JoannePrincipal Accounting OfficerSSale−272$5.53−$1.50K−0.4%66.3K after
Sep 2, 2026 (view filing)6:43 PM ETSep 11 dayFitzPatrick Margaret MDirectorPPurchase+2.10K$5.53+$11.6K+24.4%10.7K after
Aug 19, 2026 (view filing)5:58 PM ETAug 172 daysReadnour Robin ShaneDirectorSSale−35.4K$6.01−$212.7K−5.3%633.9K after2 lots10b5-1
Jul 10, 2026 (view filing)6:15 PM ETJul 82 daysEizen Joshua MSee RemarksSSale−5.95K$4.17−$24.8K−2.8%206.6K after
Jun 2, 2026 (view filing)May 294 daysWilliams Sarah JoannePrincipal Accounting OfficerSSale−265$4.43−$1.17K−0.4%66.6K after
Mar 5, 2026 (view filing)Mar 32 daysWilliams Sarah JoannePrincipal Accounting OfficerSSale−327$1.06−$346.62−0.5%66.8K after
Jan 7, 2026 (view filing)Jan 5-62 daysDay LucyChief Financial OfficerSSale−8.81K$1.01−$8.86K−10.5%75.4K after2 lots
Jan 7, 2026 (view filing)Jan 5-62 daysPrior Stephen DavidChief Strategy OfficerSSale−6.46K$1.00−$6.49K−9.9%59.1K after2 lots
Jan 7, 2026 (view filing)Jan 5-62 daysChanda SanjayChief Development OfficerSSale−9.25K$1.01−$9.31K−10.9%75.8K after2 lots
Jan 7, 2026 (view filing)Jan 5-62 daysEizen Joshua MSee RemarksSSale−24.9K$1.00−$24.9K−14.0%152.5K after2 lots
Nov 6, 2025 (view filing)Nov 42 daysEizen Joshua MSee RemarksSSale−2.82K$1.14−$3.21K−1.6%177.4K after
Nov 6, 2025 (view filing)Nov 42 daysPrior Stephen DavidChief Strategy OfficerSSale−765$1.14−$872.1−1.2%65.5K after
Jun 16, 2025 (view filing)May 2819 daysLateLeonard Braden Michael10% OwnerSSale−200.0K$1.09−$218.0K−6.2%3.02M after
Jun 3, 2025 (view filing)Jun 21 dayEasom EricChief Executive OfficerPPurchase+10.0K$1.07+$10.7K+4.1%256.4K after
May 30, 2025 (view filing)May 28-302 daysLeonard Braden Michael10% OwnerSSale−2.53M$1.13−$2.87M−44.0%3.22M after4 lots
May 29, 2025 (view filing)May 281 dayFitzPatrick Margaret MDirectorPPurchase+8.61K$1.18+$10.2KNew position8.61K after
Jan 7, 2025 (view filing)Jan 34 daysDay LucyChief Financial OfficerSSale−2.96K$1.34−$3.96K−8.3%32.7K after
Jan 7, 2025 (view filing)Jan 34 daysChanda SanjayChief Development OfficerSSale−2.96K$1.34−$3.96K−9.0%29.8K after
Jan 7, 2025 (view filing)Jan 34 daysPrior Stephen DavidChief Strategy OfficerSSale−2.03K$1.34−$2.72K−5.7%33.3K after
Jan 7, 2025 (view filing)Jan 34 daysEizen Joshua MSee RemarksSSale−9.66K$1.34−$12.9K−7.6%116.7K after
Dec 10, 2024 (view filing)Dec 6-104 daysReadnour Robin ShaneDirectorPPurchase+60.0K$1.45+$86.8K+10.1%652.6K after6 lots
Nov 27, 2024 (view filing)Nov 26-271 dayReadnour Robin ShaneDirectorPPurchase+75.0K$1.41+$105.8K+13.7%622.6K after4 lots
Nov 27, 2024 (view filing)Nov 27Same dayZakrzewski Joseph SDirectorPPurchase+2.00K$1.40+$2.80K+1.6%125.2K after
Nov 21, 2024 (view filing)Nov 19-202 daysReadnour Robin ShaneDirectorPPurchase+200.0K$1.07+$213.0K+63.5%514.8K after4 lots
Nov 20, 2024 (view filing)Nov 18-192 daysZakrzewski Joseph SDirectorPPurchase+25.0K$1.00+$25.1K+25.5%123.2K after2 lots
Nov 18, 2024 (view filing)Nov 18Same dayEasom EricChief Executive OfficerPPurchase+50.0K$1.00+$50.0K+4.9%1.07M after
Aug 14, 2024 (view filing)Aug 14Same dayLeonard Braden Michael10% OwnerPPurchase+1.50M$1.04+$1.56M+35.3%5.75M after
Aug 13, 2024 (view filing)5:03 PM ETAug 94 daysRA Capital Healthcare Fund LP and 4 others10% OwnerSSale−3.53M$1.08−$3.81M−92.1%300.9K after2 lots
Jan 19, 2024 (view filing)Jan 181 dayZakrzewski Joseph SDirectorSSale−100.0K$19.11−$1.91M−19.8%405.9K after
Jan 18, 2024 (view filing)6:18 PM ETJan 162 daysAdjuvant Global Health Technology Fund, L.P. and 3 others10% OwnerSSale−84.1K$19.65−$1.65M−4.0%2.00M after
Jan 18, 2024 (view filing)6:18 PM ETJan 162 daysAdjuvant Global Health Technology Fund, L.P. and 3 others10% OwnerSSale−15.9K$19.65−$312.6K−4.0%377.5K after
Jan 18, 2024 (view filing)Jan 162 daysAziz KabeerDirectorSSale−100.0K$19.65−$1.97M−20.9%377.5K after2 lots
Jan 17, 2024 (view filing)Jan 125 daysReadnour Robin ShaneDirectorSSale−1.43K$21.91−$31.2K−0.3%485.1K after2 lots10b5-1
Jan 12, 2024 (view filing)Jan 102 daysReadnour Robin ShaneDirectorSSale−3.67K$21.93−$80.4K−0.7%485.8K after2 lots10b5-1
Jan 11, 2024 (view filing)7:59 PM ETJan 92 daysKrause Kevin MichaelChief Strategy OfficerSSale−7.42K$20.14−$149.4K−79.5%1.91K after10b5-1
Jan 4, 2024 (view filing)6:06 PM ETJan 22 daysKrause Kevin MichaelChief Strategy OfficerSSale−2.58K$20.12−$52.0K−57.4%1.91K after10b5-1
Jan 4, 2024 (view filing)Jan 22 daysEasom EricChief Executive OfficerSSale−2.78K$20.09−$55.8K−56.6%2.13K after10b5-1
Nov 16, 2023 (view filing)6:59 PM ETNov 142 daysAdjuvant Global Health Technology Fund, L.P. and 3 others10% OwnerSSale−1.52K$16.15−$24.6K−0.1%2.08M after10b5-1
Nov 16, 2023 (view filing)6:59 PM ETNov 142 daysAdjuvant Global Health Technology Fund, L.P. and 3 others10% OwnerSSale−288$16.15−$4.65K−0.1%393.4K after10b5-1
Nov 16, 2023 (view filing)Nov 142 daysAziz KabeerDirector, 10% OwnerSSale−1.81K$16.15−$29.2K−0.5%393.4K after2 lots10b5-1
Oct 3, 2023 (view filing)7:13 PM ETSep 29-Oct 24 daysAdjuvant Global Health Technology Fund, L.P. and 3 others10% OwnerSSale−88.1K$16.27−$1.43M−4.1%2.08M after2 lots
Oct 3, 2023 (view filing)7:13 PM ETSep 29-Oct 24 daysAdjuvant Global Health Technology Fund, L.P. and 3 others10% OwnerSSale−16.7K$16.27−$271.1K−4.1%393.7K after2 lots
Oct 3, 2023 (view filing)Sep 29-Oct 24 daysAziz KabeerDirector, 10% OwnerSSale−104.8K$16.27−$1.70M−21.0%393.7K after4 lots
Sep 29, 2023 (view filing)5:41 PM ETSep 27-282 daysAdjuvant Global Health Technology Fund, L.P. and 3 others10% OwnerSSale−7.87K$16.11−$126.7K−0.4%2.17M after2 lots
Sep 29, 2023 (view filing)5:41 PM ETSep 27-282 daysAdjuvant Global Health Technology Fund, L.P. and 3 others10% OwnerSSale−1.49K$16.11−$24.0K−0.4%410.4K after2 lots
Sep 29, 2023 (view filing)Sep 27-282 daysAziz KabeerDirector, 10% OwnerSSale−9.36K$16.11−$150.7K−2.2%410.4K after4 lots
Sep 15, 2023 (view filing)5:17 PM ETSep 132 daysAdjuvant Global Health Technology Fund, L.P. and 3 others10% OwnerSSale−336$16.00−$5.38K0.0%2.18M after
Sep 15, 2023 (view filing)5:17 PM ETSep 132 daysAdjuvant Global Health Technology Fund, L.P. and 3 others10% OwnerSSale−64$16.00−$1.02K0.0%411.9K after